Moreover, reducing Mnk/p-eIF4E expression with novel RRs could also provide a therapeutic strategy for the treatment of additional aggressive cancers because Mnk1/2 and eIF4E/p-eIF4E expressions are reported to be up-regulated during progression of all types of solid tumors [9] and hematologic cancers [44]. The gene discussed is MKNK1; the disease is hematopoietic and lymphoid cell neoplasm.